Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06180109
Other study ID # PR/BE/22/266
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date July 30, 2023
Est. completion date October 6, 2023

Study information

Verified date December 2023
Source Humanis Saglik Anonim Sirketi
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

An open-label, balanced, randomized, two treatment, two sequence, two period, two way cross-over, single oral dose bioequivalence study of Empagliflozin 25 mg film coated tablets of Humanis, Turkey and Jardiance (Empagliflozin) 25 mg film-coated tablets of Boehringer Ingelheim International GmbH, Germany in normal, healthy, adult, human subjects under fasting condition.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date October 6, 2023
Est. primary completion date August 27, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: Willing to provide written informed consent for participation in the study, and an ability to comprehend the nature and purpose of the study; - Willing to be available for the entire study period and to comply protocol requirements; - Normal, healthy, adult, human subject of 18-45 years (both inclusive) of age; - Body mass index in the range of 18.50 - 30.00 kg/m2 (both inclusive); - Normal health status as determined by baseline medical and medication history, at the time of screening and vital signs measurements and physical examination at the time of screening as well as check-in of each study period; - Normal or clinically non-significant laboratory values as determined by hematological, biochemistry tests and urine analysis; - Normal or clinically non-significant 12-lead ECG recording; - Non-smokers and willing to abstain from chewing any tobacco containing products at least 72.00 hours prior to check-in until last sample collection in each study period; - Non Alcoholic; - Willing to abstain from xanthine or its derivative containing food or beverages (e.g. chocolates, tea, coffee or cola drinks), at least 48.00 hours prior to check-in until last sample collection in each study period; - Willing to abstain from grapefruit or its juice at least 72.00 hours prior to check-in until last sample collection in each study period; - For female subjects: - Negative urine pregnancy test during screening and negative serum ß-hCG test at the time of check-in of each study period; - Female subjects with child bearing potential or those within their first two years of onset of menopausal syndrome willing to either abstain from sexual intercourse, or should use of acceptable birth control methods for at least 15 days before 1st check-in till 15 days post last-dose / entire study period. [Acceptable birth control methods include barrier methods such as diaphragm/condom with or without spermicide or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy has been performed)]. Exclusion Criteria: Any medical or surgical conditions, which might significantly interfere with the functioning of gastrointestinal tract and of blood forming organs; - Significant history or current evidence of malignancy or chronic - infectious, cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic (endocrine), hematological, gastrointestinal, dermatological, immunological or psychiatric diseases, or organ dysfunction; - History of diabetes mellitus or insulin resistance. - Any major illness or hospitalized within 90 days prior to the first check-in; - Requiring medication for any ailment having enzyme-modifying activity within one month prior to first check-in and throughout the study; - Use of any depot injection or an implant of any drug within 3 months prior to first check-in and throughout the study; - Use of any prescribed medication (including herbal medicines and vitamin supplements) or OTC products within 30 days prior to first check-in and throughout the study; - History or presence of significant gastric and/or duodenal ulceration; - Difficulty in swallowing tablets or capsules; - Use of any recreational drug or history of drug addiction; - Participated in any clinical investigation requiring repeated blood sampling or have donated blood in past 90 days prior to first check-in; - Positive urine alcohol and/or urine drug of abuse tests during check-in of each study period; - Reactive test for Human Immunodeficiency Virus (HIV) type I/II antibodies or Hepatitis B surface antigen (HBsAg) or Hepatitis C virus antibodies; - Lactating or nursing female subjects; - Female subjects using hormonal contraceptive (either oral/implants); - History of allergy or hypersensitivity intolerance to Empagliflozin or its formulation excipients which, in the opinion of a clinical investigator, would compromise the safety of the subject or the study; - History of difficulty in accessibility of veins in arms.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Empagliflozin film coated tablets
1 film coated tablet of 25 mg Empagliflozin
Jardiance film-coated tablets
1 film coated tablet of 25 mg Empagliflozin

Locations

Country Name City State
India Raptim Research Pvt. Ltd., Navi Mumbai

Sponsors (1)

Lead Sponsor Collaborator
Humanis Saglik Anonim Sirketi

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum concentration obtained (Cmax) Two-sided 90% confidence intervals for ratio (test/reference) of the population means is within 80.00% to 125.00% for each of the Ln-transformed data Cmax 48 hours
Primary AUC from the 0 to infinity (AUC0-inf) Descriptive Statistics 48 hours
Primary Time of the maximum measured plasma concentration (Tmax) Descriptive Statistics 48 hours
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04082091 - Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
Active, not recruiting NCT02248311 - "Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population N/A
Completed NCT02653300 - A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH) Phase 2
Completed NCT03655535 - Multicenter Study to Evaluate the Effect of BTI320 on Glycemic Control in Type 2 Diabetes Phase 2
Completed NCT03256747 - Effects of Neuromuscular Electrical Stimulation on Glucose Variability in Patients With Type 2 Diabetes N/A
Completed NCT05343767 - Investigate the Efficacy and Safety of Low-Glu in Patients Newly Diagnosed With Type II Diabetes Mellitus N/A
Withdrawn NCT03675074 - Neujia Anastomosis for Treatment of Obesity and Type II Diabetes N/A
Withdrawn NCT03190798 - Effects of Canagliflozin on Intravascular Volume and Hemodynamics Phase 4
Withdrawn NCT03437330 - Empagliflozin Effect on Glucose Toxicity Phase 4
Withdrawn NCT03008395 - Empowerment, Motivation and Medical Adherence (EMMA). N/A
Not yet recruiting NCT05539066 - AI Health Assistant and Type 2 Diabetes N/A
Completed NCT03682445 - Metabolic, Physical Responses To Exercise In Patients With Type 2 Diabetes Mellitus N/A
Not yet recruiting NCT03239119 - The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus Phase 3
Completed NCT03259789 - Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects Phase 3
Recruiting NCT03506230 - Financial Incentives for Low Socioeconomic Diabetic Patients N/A
Completed NCT03072407 - MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM Phase 1
Completed NCT05668442 - Feasibility of an Online Exercise Community Among Individuals With Type 2 Diabetes
Completed NCT02956044 - Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin Phase 1
Completed NCT02964572 - Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes N/A
Completed NCT02628392 - A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM) N/A